高级检索
当前位置: 首页 > 详情页

Chemoradiotherapy for Synchronous Multiple Primary Cancers with Esophageal Squamous Cell Carcinoma: a Case-control Study

文献详情

资源类型:
机构: [1]Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Ctr Canc, Dept Radiat Oncol,State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China; [2]Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Ctr Canc, Dept Thorac Oncol,State Key Oncol South China, Guangzhou, Guangdong, Peoples R China; [3]Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Ctr Canc, Dept Gastr Surg,State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China; [4]Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Ctr Canc, Dept Pancreat Surg,State Key Lab Oncol South Chin, Guangzhou, Guangdong, Peoples R China; [5]Sun Yat Sen Univ, Ctr Canc, Dept Radiat Oncol, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China
出处:
ISSN:

关键词: esophageal cancer second primary malignancy chemoradiotherapy survival toxicity

摘要:
Objective: To evaluate the efficacy and toxicity of concurrent chemoradiotherapy (CRT) in multiple primary cancers (MPC) of the upper digestive tract in esophageal squamous cell carcinoma (ESCC). Methods: In a screening of 1193 consecutive patients diagnosed with ESCC and received radiotherapy, 53 patients presenting synchronous MPC in the upper digestive tract were retrospectively investigated. 53 consecutive patients with esophageal non-multiple primary cancer (NPC), matched by stage, age and sex, served as control. All of the patients received concurrent CRT. The median radiation dose was 60 Gy. Chemotherapy regimens were based on platinum and/or 5-fluorouracil. Clinical outcomes and treatment toxicities were compared. Results: Clinic-pathologic characteristics were well balanced between groups. MPC mostly located in esophagus (43, 81.8%), followed by hypopharynx (8, 15.1%) and stomach (2, 3.8%). In MPC and NPC patients, 94.3% and 96.2% completed the intended treatment. The immediate response rate was 73.6% vs 75.5%, with complete response rate of 11.3% vs 24.5% and partial response rate of 62.3% vs 51.0%. Two-year overall survival (OS), progression-free survival (PFS), locoregional progression-free survival (LRPFS) and distant progression-free survival (DPFS) were 52.2% vs 68.9% (p= 0.026), 32.9% vs 54.0% (p= 0.032), 60.8% vs 87.8% (p= 0.002) and 64.0% vs 70.8% (p= 0.22), respectively. Acute grade 3-4 toxicities were observed in 64.2% vs 54.7%, significantly higher in radiation esophagitis (49.1% vs 28.3%, p< 0.001), and mucositis (11.3% vs 00p= 0.027). Conclusions: Compared with matched NPC, ESCC accompanied with synchronous MPC was related to significantly impaired survival, elevated risk of locoregional disease progression and higher incidence of severe esophagitis and mucositis, following concurrent chemoradiotherapy. Future study on reasons for decreased efficacy of chemoradiotherapy will help to optimize treatment. Advanced radiation techniques may play a role in protecting normal tissues and reduce acute toxicities.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 3 区 医学
小类 | 3 区 肿瘤学
最新[2023]版:
大类 | 3 区 医学
小类 | 4 区 肿瘤学
第一作者:
第一作者机构: [1]Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Ctr Canc, Dept Radiat Oncol,State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China;
通讯作者:
通讯机构: [1]Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Ctr Canc, Dept Radiat Oncol,State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China; [5]Sun Yat Sen Univ, Ctr Canc, Dept Radiat Oncol, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43370 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号